Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AdaptHealth (AHCO) Depreciation & Amortization - Total (2021 - 2026)

AdaptHealth has reported Depreciation & Amortization - Total over the past 5 years, most recently at $92.5 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total rose 8.82% year-over-year to $92.5 million; the TTM value through Dec 2025 reached $361.5 million, up 5.36%, while the annual FY2025 figure was $361.6 million, 5.39% up from the prior year.
  • Depreciation & Amortization - Total for Q4 2025 was $92.5 million at AdaptHealth, roughly flat from $92.6 million in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $92.6 million in Q3 2025 and troughed at $36.9 million in Q1 2021.
  • A 5-year average of $78.9 million and a median of $85.4 million in 2024 define the central range for Depreciation & Amortization - Total.
  • Biggest five-year swings in Depreciation & Amortization - Total: surged 81.84% in 2022 and later decreased 5.96% in 2023.
  • Year by year, Depreciation & Amortization - Total stood at $65.0 million in 2021, then surged by 42.0% to $92.3 million in 2022, then dropped by 5.96% to $86.8 million in 2023, then fell by 2.07% to $85.0 million in 2024, then grew by 8.82% to $92.5 million in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for AHCO at $92.5 million in Q4 2025, $92.6 million in Q3 2025, and $87.2 million in Q2 2025.